- js reader version
- view hidden posts
- tags and related articles
by Mark Gabrish Conlan/Zenger's Newsmagazine
Saturday, Dec. 04, 2010 at 5:31 PM
firstname.lastname@example.org (619) 688-1886 P. O. Box 50134, San Diego, CA 92165
The latest marketing strategy of the AIDS establishment and Big Pharma to sell toxic "anti-HIV" drugs at exorbitant prices is a sinister development called "pre-exposure prophylaxis." This is the idea of selling the drugs to HIV NEGATIVE Gay and Bisexual men engaged in so-called "high-risk" sexual lifestyles, supposedly to keep them from becoming infected. But it actually appears to be the industry looking for another market in the face of the recession, which is likely to reduce government and philanthropic funding for HIV meds in the developing world and thereby derail the pharmaceutical gravy train of AIDS. Fortunately, today's Gay men have got out of the intense fear of AIDS that ruled the Queer community in the 1980's and 1990's and are therefore unlikely to fall for the siren call of "pre-exposure prophylaxis."
“Pre-Exposure Prophylaxis”: Big Pharma's Latest AIDS Drug Marketing Strategy
commentary by MARK GABRISH CONLAN
Copyright © 2010 by Mark Gabrish Conlan for Zenger's Newsmagazine * All rights reserved
“Pill Is Found to Cut Risk of HIV,” read a headline in the November 23 Los Angeles Times that reported on a study in the New England Journal of Medicine that claimed giving an anti-HIV medication called Truvada (actually a pill containing two drugs, emtricitabine and tenofovir), reduced the risk of so-called “HIV transmission” between Gay men leading “high-risk” sexual lifestyles. The study, conducted by an international team headed by Dr. Robert M. Grant of the Gladstone Institute of Virology and Immunology at UC San Francisco and Dr. Javier R. Lama of Investigaciones Medicas en Salud in Lima, Peru, enrolled 2,499 Gay men and male-to-female Transgender people and gave half of them a once-a-day dose of Truvada and half of them a harmless placebo.
The results, observed over 14 months, were that 36 people in the Truvada group “seroconverted” – went from testing HIV antibody-negative to antibody-positive – versus 64 in the control group. The Los Angeles Times article noted that the difference between 36 and 64 was 43.8 percent, and that “the reduction in risk … was very sensitive to how regularly the subjects took the medication.” For those who took their daily dose more than 50 percent of the time, the article reported, the seroconversion rate fell by 50.2 percent. For those who took the drug more than 90 percent of the time, the rate fell by 72.8 percent.
Notice that the Times report was framed in a way that completely ignored another fact shown by those numbers: how unlikely it is, even for Gay and Transgender people picked specifically for their “high-risk” sexual practices and therefore their vulnerability to sexually transmitted diseases, to become “HIV positive” in the first place. Of the total number of people in the study, just 100 seroconverted – 4 percent. Assuming that both the Truvada and the control group were of equal size, which is the standard practice, the conversion rate among the people taking the drug was 2.9 percent and among the people on placebo was 5.1 percent.
For decades sexually active Gay men have been fed a steady diet of propaganda about how supposedly easy it is to get HIV – to the point where it's backfired, convincing a lot of people that it doesn't pay to use condoms or otherwise reduce sexual risks because seroconversion isn't a matter of “if,” but “when” – yet here is hard evidence from an establishment source of just how difficult it is to become “HIV positive” from sex. But that isn't stopping the AIDS establishment from declaring yet another “victory.”
The initial Los Angeles Times report was followed up by two additional articles. The first came out November 24, the day after the initial piece, and was by the same author, science reporter Thomas Maugh II. It was called “Anti-HIV Pill's Trial Success Rekindles Hope” and quoted researcher Grant as saying that they had “tried all the easy things” to prevent HIV seroconversion, and now, “We had to embolden ourselves to consider something like a pill a day, even though it is expensive and requires medical monitoring.” When he said the pills were expensive, he wasn't kidding; later in the article Maugh reported that Truvada costs ,000 to ,000 per year, and like most anti-HIV medications it's not available in a cheaper generic form. What's more, Maugh reported, it probably won't be covered by health insurance because Truvada is currently approved only for anti-HIV treatment, not prevention – and a lot of people might not want the drug anyway because it will mean “outing” themselves in their medical records as Gay men leading “high-risk” sexual lifestyles.
A third Times story, a November 29 op-ed by International AIDS Vaccine Initiative CEO Seth Berkley, both added to the myth-making and offered some fascinating clues as to why the long talked-about strategy of “pre-exposure prophylaxis” – giving anti-HIV drugs to HIV antibody-negative people in hopes of keeping them from seroconverting – is suddenly being pushed now, 17 years after it was first broached at the 1993 international AIDS conference in Berlin. “Thanks largely to AIDS activists who demanded expedited research and approvals, today there are more drugs licensed to treat HIV than there are for all other viruses combined,” Berkley wrote. “Generous donors and innovative pricing mechanisms have made these antiretroviral drugs available to about 36 percent of those in the developing world who [allegedly] need them to stay alive and healthy.”
But even with those so-called “innovative pricing mechanisms” – basically discounts that reduce the drug companies' profits on them from obscene to merely swollen – it's getting harder for the AIDS establishment to persuade governments, international agencies and private donors to keep coming up with the huge levels of funding needed to buy anti-HIV medications for all the people the establishment says “need” them. According to Berkley, this year the Global Fund to Fight AIDS, Tuberculosis and Malaria committed billion to buy these drugs – “ billion less than the minimum amount … needed.” In the face of a global economic downturn and the election victories of austerity-minded Right-wing parties in the U.S. and western Europe's three largest countries – Britain, France and Germany – Berkley and other AIDS establishmentarians worry that donors won't “continue making the enormous investment required to provide access to treatment to all those living with HIV” without “reasonable assurance that one day the bill will be paid in full. This will require having ways to reliably prevent new infections.”
Throughout its quarter-century existence, the AIDS establishment's number one priority has been the development, merchandising and selling of high-priced anti-HIV “treatments.” In the 1980's drug companies were actually unwilling to invest money in creating and marketing AIDS drugs because they didn't think there'd ever be enough people with full-blown AIDS to make them profitable. That changed in 1989, when the Burroughs-Wellcome company (now part of GlaxoSmithKline) got its first anti-AIDS drug, AZT, approved by the U.S. Food and Drug Administration (FDA) not only for people actually sick from AIDS but for otherwise completely healthy people who tested “HIV positive.” The market for AIDS drugs zoomed upward – though the high toxicity of AZT and other early AIDS drugs killed off a lot of their customers – and it zoomed up again after 1996, when doses of AZT and other first-generation drugs were reduced and they were combined with protease inhibitors and other sorts of drugs that were less toxic.
But the markets for anti-HIV medications in the U.S. and other developed countries started flatlining in the late 1990's, as fewer Gay and Bisexual men took the HIV antibody test – the gateway to being declared “sick” and in need of such “treatment” – and as fewer of them died of AIDS. AIDS moved from epidemic to endemic, and in the process many Gay and Bisexual men either lost their fear of it or, in the case of young people just entering sexual activity, never got deathly afraid of AIDS in the first place. The AIDS establishment needed new markets for their drugs, and they found them first among people of color in the developed countries, then among people of color in their home countries. The U.N. AIDS program obediently created mountains out of molehills of statistical data to proclaim that Africa, and later Asia, were inundated with “HIV positive” people who didn't know it and this threatened the very survival of countries in those regions.
Since these nations and their people didn't have the money to pay for anti-HIV drugs themselves, the AIDS establishment started a campaign of shaming the people who did – governments and rich people in developed countries – to cover the cost. “Helping” the Third World by providing their people anti-HIV drugs (for medical conditions that could have been addressed far more effectively through clean water, sanitation, adequate diet and simple antibiotics to use against genuine health threats like malaria and TB) became a personal charitable priority of the two richest men in the world, Bill Gates and Warren Buffett, as well as plenty of politicians and officials in non-governmental organizations (NGO's) looking at what sorts of health-care projects to fund in the less-developed world. But, as Berkley admitted in his article, the recession is drying up that gravy train and forcing the drug companies to turn away from the Third World and look again for customers who actually have money.
Hence the turn towards “pre-exposure prophylaxis” that can be sold to Gay men in developed countries as a way of not needing to worry about AIDS – even though that will mean condemning themselves to a lifetime of medical monitoring and will essentially redefine being Gay itself as a “disease” needing “treatment.” It will also mean confronting the adverse (so-called “side”) effects of these drugs, including nausea, serum creatinine increases (which in the normal medical world is often a sign of kidney failure) and “unintentional weight loss.” (A little-noticed paper read at the 2004 international AIDS conference in Barcelona said that the number one cause of death among people diagnosed “HIV positive” today is liver failure from the toxicities of anti-HIV drugs.) Quite a few much-ballyhooed AIDS drug regimens in the past have turned out to have had devastating “side” effects that weren't discovered until well after the drugs were mass-marketed because the AIDS establishment has a way of stopping their trials early before all the adverse effects are known – though, to their credit, Grant and Lama are keeping their study going for another 18 months to assess long-term risks.
My thought is that not very many developed-world Gay men are going to fall for the lure of “pre-exposure prophylaxis.” Had this been announced 15 or even 10 years ago, while the AIDS scare was at its height, Gay men might have rushed to their doctors and asked to be prescribed these regimens. Now that AIDS has long since ceased to be either a consuming emotional issue in the Queer community or a particularly trendy charity – the “in” cause among Queer philanthropists and organizations right now is reaching out to Queer teenagers and keeping them from committing suicide or ending up homeless – it's likely that the thought of spending thousands of dollars on anti-HIV drugs before you've even seroconverted is going to go over like a family-planning convention inside Vatican City. But I've been proven wrong before about the AIDS establishment and its ability to make money and maintain prestige despite the patent absurdity of most of their “science” and their inability to deliver either a “cure” or a workable “vaccine” against an elusive “virus” that doesn't behave anything like an ordinary sexually transmitted microbe.
Report this post as:
GUIDE TO REBEL CITY LOS ANGELES AVAILABLE
lausd whistle blower
Help KCET and UCLA identify 60s-70s Chicano images
UCLA Luskin: Casting Youth Justice in a Different Light
Change Links April 2018
Nuclear Shutdown News March 2018
Join The Protest Rally in Glendale on April 10, 2018!
Join The Protest Rally in Glendale on April 10, 2018!
Spring 2018 National Immigrant Solidarity Network News Alert!
Anti-Eviction Mapping Project Shows Shocking Eviction Trends in L.A.
Steve Mnuchin video at UCLA released
Actress and Philanthropist Tanna Frederick Hosts Project Save Our Surf Beach Clean Ups
After Being Told He's 'Full of Sh*t' at School Event, Mnuchin Demands UCLA Suppress Video
Resolution of the Rent Strike in Boyle Heights
What Big Brother Knows About You and What You Can Do About It
Step Up As LAPD Chief Charlie Beck Steps Down
Our House Grief Support Center Hosts 9th Annual Run For Hope, April 29
Don’t let this LA County Probation Department overhaul proposal sit on the shelf
Echo Park Residents Sue LA Over Controversial Development
Former Signal Hill police officer pleads guilty in road-rage incident in Irvine
Calif. Police Accused of 'Collusion' With Neo-Nazis After Release of Court Documents
Center for the Study of Political Graphics exhibit on Police Abuse posters
City Agrees to Settle Lawsuit Claiming Pasadena Police Officer Had His Sister Falsely Arre
Professor's Study Highlights Health Risks of Urban Oil Drilling
Claims paid involving Pasadena Police Department 2014 to present
Pasadenans - get your license plate reader records from police
LA Times Homicide Report
More Local News...
Biodiversité ou la nature privatisée
The Market is a Universal Totalitarian Religion
Book Available about Hispanics and US Civil War by National Park Service
The Shortwave Report 04/20/18 Listen Globally!
The Republican 'Prolife' Party Is the Party of War, Execution, and Bear Cub Murder
Paraphysique de la dictature étatique
Book Review: "The New Bonapartists"
The West Must Take the First Steps to Russia
Théorie générale de la révolution ou hommage à feu Mikhaïl Bakounine
The Shortwave Report 04/13/18 Listen Globally!
“Lost in a Dream” Singing Competition Winner to Be Chosen on April 15 for ,000 Prize!
The World Dependent on Central Banks
Ohio Governor Race: Dennis Kucinich & Richard Cordray Run Against Mike DeWine
March 2018 Honduras Coup Again Update
Apologie du zadisme insurrectionnel
ICE contract with license plate reader company
Black Portraiture(S) IV: The Color of Silence...Cuba No...Cambridge Yes
Prohibiting Micro-Second Betting on the Exchanges
Prosecutors treat Muslims harsher than non-Muslims for the same crimes
Amy Goodman interview on cell phone safety
Mesa, Arizona police officer kills unarmed white man
Israeli leaders should be prosecuted for war crimes
Paraphysique de l'autorité
Two Podcasts on fbi corruption
Fbi assassins assault & try to kill DAVID ATKINS
EPA Head Scott Pruitt: Of Cages And Sirens
More Breaking News...